- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
202-B - Baby Steps: Updates in the Treatment of Infant Leukemia (Ballroom A) - Feb 27, 2024 - Abstract #HOPA2024HOPA_33;
This breakout session will review appropriate management to arm healthcare professionals to treat these complex patients. Additionally, recently published literature, including upfront blinatumomab, will be discussed along with practical considerations for implementing these changes.Learning Objectives:
- |||||||||| Lumakras (sotorasib) / Amgen
Non-CE Symposia: Managing Patients with locally advanced or metastatic KRAS G12C-mutated NSCLC (122-123) - Feb 27, 2024 - Abstract #HOPA2024HOPA_18;
Additionally, recently published literature, including upfront blinatumomab, will be discussed along with practical considerations for implementing these changes.Learning Objectives: Hatim Husain of Moores of UC San Diego Health on "Managing Patients with KRAS G12C-mutated NSCLC," highlighting LUMAKRAS
- |||||||||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Review, Journal, Adverse events: Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment. (Pubmed Central) - Feb 27, 2024
The review encompasses the underlying molecular and cellular mechanisms of cardiotoxicity, associated risk factors, and diagnostic methods. Additionally, we provide information on several available treatments and drug choices for angina resulting from 5-FU exposure, including nicorandil, ranolazine, trimetazidine, ivabradine, and sacubitril-valsartan, which have demonstrated potential in mitigating or protecting against chemotherapy-induced adverse cardiac effects.
- |||||||||| Lumakras (sotorasib) / Amgen
Review, Journal, PD(L)-1 Biomarker, IO biomarker: KRAS G12C-mutant driven non-small cell lung cancer (NSCLC). (Pubmed Central) - Feb 27, 2024
Exploring these pathways as therapeutic targets and their impact on different chemotherapeutic agents (carboplatin, paclitaxel) is crucial. Comutations in STK11/LKB1 often co-occur with KRAS G12C, jeopardizing the effect of immune checkpoint (anti-PD1/PDL1) inhibitors.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Review, Journal, Metastases: Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer. (Pubmed Central) - Feb 26, 2024
Ribociclib may be indicated for pre/perimenopausal patients, whereas abemaciclib is potentially recommended to address endocrine-resistant or visceral disease. Alternatively, palbociclib is associated with lower discontinuation rates than abemaciclib and unlike ribociclib, QTc prolongation is not observed with palbociclib.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Awareness of Medication-Related Osteonecrosis of the Jaws Amongst Patients on Antiresorptive and Antiangiogenic Medications. (Pubmed Central) - Feb 26, 2024
It primarily affects individuals undergoing treatment with antiresorptive and antiangiogenic medications, such as bisphosphonates and denosumab, commonly prescribed for osteoporosis and cancer-related bone metastases...Conclusion Notably, a small percentage of participants demonstrated awareness of this condition, indicating a need for continued education and awareness campaigns. Further research and interventions may be warranted to address the specific needs of different age groups and educational backgrounds in promoting safe and effective medication management.
- |||||||||| Review, Journal: Biosimilar in Breast Cancer: A Narrative Review. (Pubmed Central) - Feb 26, 2024
Further research and interventions may be warranted to address the specific needs of different age groups and educational backgrounds in promoting safe and effective medication management. Trastuzumab biosimilars, such as CT-P6, Ontruzant
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost and cost-effectiveness of immunotherapy in childhood ALL: A systematic review. (Pubmed Central) - Feb 26, 2024
No studies have evaluated blinatumomab or inotuzumab ozogamicin...The cost-effectiveness of tisagenlecleucel was highly dependent on list price and cure rates. This study can inform the use of tisagenlecleucel in pALL.
- |||||||||| Remicade (infliximab) / J&J, Blincyto (blinatumomab) / Astellas, Amgen
Preclinical, Journal, Cytokine release syndrome: Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model. (Pubmed Central) - Feb 26, 2024
BRGSF mice reconstituted with human umbilical cord blood CD34+ cells (BRGSF-CBC) were injected with anti-CD3 antibody (OKT3), anti-CD3/CD19 bispecific T-cell engager Blinatumomab, or VISTA-targeting antibody...Clinical CRS-managing treatment Infliximab efficiently attenuated OKT3-induced toxicity...These data show that BRGSF-CBC mice represent a relevant model for the preclinical assessment of CRS and CRS-managing therapies. They also confirm a significant role of myeloid and dendritic cells in CRS development and exhibit the versatility of this model for therapeutics-induced safety assessment.
- |||||||||| Ostarine (enobosarm) / Veru Inc
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: ENABLAR-2: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Feb 26, 2024
P3, N=5, Terminated,
Pembrolizumab in combination with platinum-etoposide therapy had manageable toxicity with no new safety signals and was associated with antitumor activity in Japanese patients with ES-SCLC. N=186 --> 5 | Trial completion date: Dec 2025 --> Jan 2024 | Suspended --> Terminated | Trial primary completion date: Dec 2025 --> Oct 2023; Business decision
- |||||||||| ivabradine / Generic mfg.
Review, Journal: Hyperpolarization-activated cyclic nucleotide-gated channel inhibitor in myocardial infarction: Potential benefits beyond heart rate modulation. (Pubmed Central) - Feb 26, 2024
There is an accumulation of intriguing evidence to suggest that ivabradine also possesses cardioprotective effects that are independent of heart rate reduction. This review aims to summarize and discuss the reported cardioprotective mechanisms of ivabradine beyond heart rate modulation in myocardial infarction through various molecular mechanisms including the prevention of reactive oxygen species-induced mitochondrial damage, improvement of autophagy system, modulation of intracellular calcium cycling, modification of ventricular electrophysiology, and regulation of matrix metalloproteinases.
- |||||||||| Journal: Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer. (Pubmed Central) - Feb 26, 2024
P1/2
The recently approved KRASG12C mutation-specific inhibitors sotorasib and adagrasib (KRASG12C-I) represent a promising therapy for KRASG12C-driven non-small cell lung cancer (NSCLC)...Tissue factor (TF) is overexpressed in KRAS-mutated (KRASmut) NSCLC and is the target of the FDA-approved ADC Tivdak...Thus, we have identified the TF/mTORC2 axis as a critical new mechanism for triggering immunosuppression and KRAS-I resistance. We propose that targeting this axis with HuSC1-39 or MTI-31 will improve KRAS-I response in KRAS-driven NSCLC.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal, CAR T-Cell Therapy: Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet? (Pubmed Central) - Feb 26, 2024
However, these agents have their own challenges including the limited durability of remission, the need for additional concurrent chemotherapy and the prolonged course of treatment, and limited efficacy in the setting of extramedullary disease. Here, we hypothesize that the incorporation of chimeric antigen receptor (CAR) T cell therapy as a consolidation treatment in older adults with B-cell ALL in their first complete remission is the ideal setting to advance treatment outcomes by reducing treatment toxicity, enhancing remission durability, and expanding the use of this effective therapy in this age population.
- |||||||||| ivabradine / Generic mfg.
Journal: Heart rate lowering for coronary CTA with Ivabradine in atrial fibrillation. (Pubmed Central) - Feb 26, 2024
Here, we hypothesize that the incorporation of chimeric antigen receptor (CAR) T cell therapy as a consolidation treatment in older adults with B-cell ALL in their first complete remission is the ideal setting to advance treatment outcomes by reducing treatment toxicity, enhancing remission durability, and expanding the use of this effective therapy in this age population. No abstract available
- |||||||||| Prolia (denosumab) / Amgen
Journal: RANKL inhibition reduces lesional cellularity and G?s variant expression and enables osteogenic maturation in fibrous dysplasia. (Pubmed Central) - Feb 25, 2024
P2
The results from this study demonstrated that, in addition to its expected antiosteoclastic effect, denosumab reduces FD lesion activity by decreasing FD cell proliferation and increasing osteogenic maturation, leading to increased bone formation within lesions. These findings highlight the unappreciated role of cellular crosstalk between osteoclasts and preosteoblasts/osteoblasts as a driver of FD pathology and demonstrate a novel mechanism of action of denosumab in the treatment of bone disease.TRIAL REGISTRATION: ClinicalTrials.gov NCT03571191.
- |||||||||| Sulonex (sulodexide) / Alfasigma, Enbrel (etanercept) / Pfizer, Amgen
Journal, Surgery: The significance of glycocalyx in surgery. (Pubmed Central) - Feb 25, 2024
These findings highlight the unappreciated role of cellular crosstalk between osteoclasts and preosteoblasts/osteoblasts as a driver of FD pathology and demonstrate a novel mechanism of action of denosumab in the treatment of bone disease.TRIAL REGISTRATION: ClinicalTrials.gov NCT03571191. Further research needs to be performed to evaluate the effect of endothelium-protectives on glycocalyx damage prevention and repair in ischaemia and reperfusion models involving large laboratory animals or in clinical trials in patients undergoing surgical revascularisation procedures.
- |||||||||| HRX-0233 - HepaRegeniX, Netherlands Cancer Institute / Antoni van Leeuwenhoek, Lumakras (sotorasib) / Amgen
Journal: Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers. (Pubmed Central) - Feb 24, 2024
We find that the combination of sotorasib, a drug targeting KRASG12C, and the MAP2K4 inhibitor HRX-0233 prevents this feedback activation and is highly synergistic in a panel of KRASG12C-mutant lung and colon cancer cells. Moreover, combining HRX-0233 and sotorasib is well-tolerated and resulted in durable tumor shrinkage in mouse xenografts of human lung cancer cells, suggesting a therapeutic strategy for KRAS-driven cancers.
- |||||||||| Review, Journal: Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management. (Pubmed Central) - Feb 24, 2024
Biologic DMARDs (bDMARDs) like infliximab, rituximab, etanercept, adalimumab, tocilizumab, certolizumab pegol, and abatacept have greater effectiveness with fewer adverse effects in comparison to non-biologic DMARDs...The main focus of this review article is to highlight the potential role of nanotechnology in the drug delivery of DMARDs for increasing solubility, dissolution, and bioavailability for the improved management of RA. This article also focusses on the different aspects of nanoparticles like their applications in biologics, biocompatibility, body clearance, scalability, drug loading, and stability issues.
- |||||||||| Review, Journal: Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma. (Pubmed Central) - Feb 24, 2024
This review analyzes current knowledge on the IL-4/IL-13 axis in mycosis fungoides and Sezary syndrome, the most common types of CTCL, examining existing literature on the pathogenetic implications with a focus on investigational treatments. Clinical trials and case reports are required to shed light on novel uses of medications in various diseases, and ongoing research into the role of IL-4/IL-13 axis blockers in CTCL therapy might not only improve the management of disease-related pruritus but also provide in-depth insights on the pathophysiologic mechanisms of CTCL.
- |||||||||| Ibrance (palbociclib) / Pfizer
Journal: Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer. (Pubmed Central) - Feb 24, 2024
Herein, a multifunctional ICD inducer is purposefully developed A6-MPDA@PAL by integrating photothermal therapy (PTT) nanoplatforms mesoporous polydopamine (MPDA), CDK4/6 inhibitor palbociclib (PAL), and CD44-specific targeting A6 peptide in a simple way for augmenting the immune antitumor efficacy of anti-PD-L1 therapy...Together with stronger accumulative ICD induction, single administration of A6-MPDA@PAL can trigger robust systemic antitumor immunity and abscopal effect with the assistance of anti-PD-L1 blockade by fascinating the intratumoral infiltration of T lymphocytes and reversing the immunosuppressive tumor microenvironment simultaneously, therapy achieving brilliant synergistic immunotherapy with effective tumor ablation. This study presents a simple and smart ICD inducer opening up attractive clinical possibilities for reinforcing the anti-PD-L1 therapy against breast cancer.
- |||||||||| Retrospective data, Journal: Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study. (Pubmed Central) - Feb 23, 2024
Fremanezumab was not included due to unavailability in the UAE...The safety of switching between CGRP classes was well observed, as any adverse events presented before the class switch did not lead to the discontinuation of treatment following the later switch. The findings of this study suggest that switching between different classes of CGRP mAbs is a potentially safe and clinically viable practice that may have some applications for those experiencing side effects on their current CGRP mAb or those witnessing suboptimal response.
- |||||||||| Prolia (denosumab) / Amgen, Tagrisso (osimertinib) / AstraZeneca
Review, Journal, Monotherapy: Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension? (Pubmed Central) - Feb 23, 2024
Our case is a further report that could be intended as an alert both for oncologists and dentists to share decisions about the oral management of such patients together, also informing them about this possible risk. Also, this report could trigger in the scientific community the necessity to evaluate further guidelines for similar doubtful cases in which the drug interaction, the mono-suspension, and the possible removable prosthesis-related additional trauma should be considered causes or con-causes.
- |||||||||| Lumakras (sotorasib) / Amgen
Journal, Combination therapy: A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor. (Pubmed Central) - Feb 23, 2024
Importantly, the combination of 23 with AMG510 suppressed RAS signaling feedback activation, showing synergistic effects against KRASG12C mutant cells in vitro and in vivo. Our findings demonstrated that KRASG12C inhibition plus SOS1 degradation as a potential therapeutic strategy to improve antitumor response and overcome acquired resistance to KRASG12C inhibitor.
- |||||||||| camsirubicin (MNPR-201) / Monopar Therap
Phase classification, Trial primary completion date, Metastases: Camsirubicin + Pegfilgrastim to Determine MTD in ASTS (clinicaltrials.gov) - Feb 23, 2024
P1, N=21, Recruiting,
However, further prospective studies are warranted to establish their efficacy in this population. Phase classification: P1b --> P1 | Trial primary completion date: Jun 2023 --> Jun 2025
|
